China NMPA Approves Uscom BP+
SYDNEY, Australia, Mon SYDNEY, Australia, Monday19th April,2021: Uscom Limited (ASX code: UCM) (the Company Company Company or Uscom) today notified the market that its patent protected high fidelity central blood pressure monitor, BP+, has received Chinese National Medical Products Administration (NMPA) approval for sale into China. The NMPA certificate will be issued within the next 10 working days.
The approval follows a rigorous 26 months’ process of testing and validation of the technology and now allows the Uscom BP+ to be sold in China, contributing a new sales revenue stream to Uscom.
27th January 2021
4C Quarterly Cash Report to 31 December 2020
Cash receipts $1.91m - up 149%
Sales revenue $0.98m – up 125%
Cash flow positive $0.29m
Cash on hand $2.28m, up $0.80m
Nice 4C today.
My conversation with CEO from Sept 2, 2020
Uscom (UCM) with Professor Robert Phillips, CEO
Director buying on-market. This quarter's EPS will be very interesting - indications of large orders of USCOM 1A device to fit out 51 COVID Hospitals in China.